The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Estrogen and Progesterone Receptors in Breast Cancer
Abstract
Breast cancer is the most common cancer in women worldwide. The majority of breast cancers show overexpression of estrogen receptors (ERs) and progesterone receptors (PRs). The development of drugs to target these hormone receptors, such as tamoxifen, has brought about significant improvement in survival for women with hormone receptor-positive breast cancers. Since information about ER and PR is vital for patient management, quality assurance is important to ensure accurate testing. In recent guidelines, the recommended definition of ER and PR positivity is 1% or more of cells that stain positive. Semiquantitative assessment of ER and PR is important for prognosis and, hence, management. Even with the development of genomic tests, hormone receptor status remains the most significant predictive and prognostic biomarker.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of ASCO/CAP guidelines for determining ER status on molecular subtype
Deyarmin, B., Kane, J. L., Valente, A. L., van Laar, R., Gallagher, C., Shriver, C. D., & Ellsworth, R. E. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2588-8 · Cited by 149
Cited by
Sex hormone signaling and regulation of immune function
Hoffmann, J. P., Liu, J. A., Seddu, K., & Klein, S. L. (2023) · Immunity · doi:10.1016/j.immuni.2023.10.008 · Cited by 344
Most recent strategies targeting estrogen receptor alpha for the treatment of breast cancer
Kumar, N., Gulati, H. K., Sharma, A., Heer, S., Jassal, A. K., Arora, L., Kaur, S., Singh, A., Bhagat, K., Kaur, A., et al. (2021) · Molecular Diversity · doi:10.1007/s11030-020-10133-y · Cited by 37
Metadata
- Authors
- Yip, C.-H., & Rhodes, A.
- Venue
- Future Oncology
- Publisher
- Informa UK Limited
- Published
- 2014-11
- Volume
- 10
- Issue
- 14
- Pages
- 2293-2301
- ISSN
- 1479-6694 (ISSN-L)
- 1744-8301
- OpenAlex
- W2023926251
- Cited by
- 208
- References
- 1
- FWCI
- 1.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.